THE NICKLES GROUP, LLC for AMGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Issues related to cardiovascular care. Issues related to pharmacy benefit management. Issues related to Medicaid prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Health Issues HCR
Issues related to pharmacy benefit management.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Copyright/Patent/Trademark CPT
S. 79, Interagency Patent Coordination and Improvement Act of 2023. S. 150, Affordable Prescriptions for Patients Act of 2023. Issues concerning mergers and acquisitions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF CHOUDHRY | — |
| GREG D'ANGELO | — |
Taxation/Internal Revenue Code TAX
S. 866, the American Innovation & Jobs Act and H.R. 3938, Build It in America Act, and issues related to the R&D tax credit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RACHEL JONES HENSLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.